GlassScriptPhysician profile
Simon Bessette
NPI 1942767264
$45,641.71
in general payments reported to CMS, 2019-2025
52 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.53 · 2022: $4,504 · 2023: $6,468 · 2024: $11K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $675 · Travel and Lodging: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20,821.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,225.00 |
| Consulting Fee | $675.00 |
| Travel and Lodging | $365.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,638.06 | 2022-2025 | |
| Pfizer INC. | $3,341.91 | 2021-2025 | |
| Lundbeck LLC | $2,392.92 | 2022-2025 | Vyepti, Rexulti |
| Ucb, INC. | $1,908.82 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $1,162.28 | 2022-2025 | |
| Neurelis, INC. | $1,152.72 | 2022-2025 | Valtoco |
| Impel Pharmaceuticals INC. | $953.22 | 2022-2023 | Trudhesa |
| Axsome Therapeutics, INC. | $905.44 | 2023-2025 | Symbravo, Auvelity |
| Teva Pharmaceuticals USA, INC. | $882.09 | 2022-2025 | Ajovy, Austedo, Austedo Xr |
| Catalyst Pharmaceuticals, INC. | $739.20 | 2023-2025 | Fycompa |
| Sk Life Science, INC. | $720.40 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $706.48 | 2022-2025 | Qelbree, Qelbree, Oxtellar Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $701.24 | 2022 | |
| Lilly USA, LLC | $657.34 | 2022-2025 | Emgality, Reyvow, Zepbound |
| Azurity Pharmaceuticals, INC. | $613.39 | 2024-2025 | Zonisade, Horizant |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $413.61 | 2022-2025 | Dysport |
| Ironshore Pharmaceuticals INC. | $404.85 | 2022-2024 | Jornay Pm |
| Livanova USA, INC. | $402.20 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $361.25 | 2024-2025 | Daybue |
| Merz Pharmaceuticals, LLC | $330.95 | 2022-2025 | Xeomin, Inbrija |
| Neos Therapeutics, LP | $309.15 | 2022-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Biocodex, INC. | $283.10 | 2023-2025 | Diacomit |
| Tonix Medicines, INC. | $248.56 | 2024-2025 | Zembrace Symtouch |
| Sumitomo Pharma America, INC. | $239.61 | 2023-2024 | Aptiom |
| Amgen INC. | $235.75 | 2022-2023 | Aimovig |
| Immedica Pharma US, INC. | $229.34 | 2022-2025 | Ztalmy |
| Otsuka America Pharmaceutical, INC. | $228.51 | 2023-2024 | Rexulti |
| Corium, LLC | $227.54 | 2022-2025 | Azstarys |
| Tris Pharma INC | $225.00 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Scilex Pharmaceuticals INC. | $218.34 | 2023-2025 | Ztlido |
| Upsher-Smith Laboratories LLC | $216.77 | 2022 | |
| Alexion Pharmaceuticals, INC. | $195.85 | 2022-2025 | Strensiq |
| Collegium Pharmaceutical, INC. | $187.51 | 2022-2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $186.14 | 2022 | |
| Eisai INC. | $185.81 | 2022-2023 | |
| Otter Pharmaceuticals, LLC | $180.35 | 2025 | Sympazan |
| Aquestive Therapeutics, INC. | $150.28 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $100.45 | 2024-2025 | Spravato |
| Janssen Biotech, INC. | $61.36 | 2025 | |
| Aucta Pharmaceuticals, INC. | $55.27 | 2024-2025 | Motpoly Xr |
| Biogen, INC. | $46.17 | 2024-2025 | Skyclarys |
| Takeda Pharmaceuticals U.S.A., INC. | $33.21 | 2023 | |
| Impel Pharmaceuticals LLC | $30.19 | 2024-2025 | Trudhesa |
| Springworks Therapeutics, INC. | $29.59 | 2025 | Gomekli |
| Glaxosmithkline, LLC. | $28.88 | 2021-2022 | |
| Itf Therapeutics LLC | $24.10 | 2024 | |
| Noven Therapeutics, LLC | $23.74 | 2023 | Xelstrym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.17 | 2024 | Caplyta |
| Amneal Pharmaceuticals LLC | $15.87 | 2023 | Lyvispah |
| Sanofi Pasteur INC. | $12.41 | 2021 | |
| Merck Sharp & Dohme LLC | $12.17 | 2021 | |
| Aytu Biopharma, INC. | $9.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Bessette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.